November 11, 2026

HPA-Global strategic regulatory partner CIRS Group has announced another successful international regulatory project, helping Chinese ingredient manufacturer Henan Zhongda Hengyuan Biotechnology secure regulatory milestones for its D-allulose ingredient in both the United States and China.
On November 9, China’s National Health Commission (NHC) added Zhongda Hengyuan’s D-allulose to its terminated-review list, concluding that the ingredient was substantially equivalent to previously approved D-allulose.
The ingredient is manufactured from fructose using an authorized D-allulose 3-epimerase enzyme, followed by purification and processing. China’s substantial-equivalence determination recognizes that this production method and resulting ingredient meet applicable equivalence requirements relative to an existing authorization.
D-allulose, also known as D-psicose, is a rare sugar used as a lower-calorie alternative to conventional sugar. It provides approximately 0.4 calories per gram and has attracted growing interest from food, beverage, and nutritional product manufacturers developing reduced-sugar formulations.
The Chinese regulatory milestone follows an earlier successful U.S. regulatory submission. With support from CIRS, Zhongda Hengyuan received an FDA “no questions” response on July 6, 2026, for its D-allulose ingredient under GRAS Notice No. GRN 001309.
According to CIRS, the U.S. process took approximately four months from FDA filing acceptance to receipt of the response letter.
In China, the application was formally accepted on May 26, 2026, and completed on November 9, less than six months later.
CIRS reports that it has now assisted three companies in obtaining either new food ingredient approval or substantial-equivalence determinations for D-allulose in China.
Zhongda Hengyuan specializes in natural food colors, functional ingredients, sweeteners, and biotechnology-based manufacturing. The company has developed large-scale enzymatic conversion technology for producing D-allulose to serve growing international demand for reduced-sugar ingredients.
The regulatory outcomes represent important commercial milestones. However, the FDA response is not a formal approval of the ingredient, and China’s substantial-equivalence determination is not a separate new food ingredient approval. Both outcomes remain subject to applicable ingredient specifications, conditions of use, and other regulatory requirements.
What This Means for the Industry
This development highlights the growing importance of coordinated international regulatory strategies for Chinese nutritional ingredient manufacturers seeking access to multiple markets.
As demand for sugar alternatives increases, D-allulose is attracting attention from manufacturers of functional foods, beverages, and nutritional products. Successful regulatory submissions in major markets can help ingredient suppliers strengthen their international competitiveness and provide customers with greater confidence in ingredient compliance.
The project also demonstrates the international regulatory capabilities of HPA-Global strategic partner CIRS Group. By supporting both U.S. GRAS notifications and Chinese new food ingredient procedures, CIRS can help companies navigate differing regulatory requirements and potentially accelerate market-entry timelines.
For ingredient manufacturers developing new production technologies, the substantial-equivalence pathway may offer an alternative to a full new food ingredient review when a product can demonstrate equivalence to an existing authorization.
The successful completion of this project provides another example of how experienced regulatory support can help companies commercialize innovative ingredients across international markets.
Sources:
- CIRS Group – From U.S. FDA GRAS to China Substantial Equivalence: CIRS Supports Zhongda Hengyuan’s D-Allulose, November 11, 2026
- U.S. FDA – GRAS Notice GRN 001309, Henan Zhongda Hengyuan Biotechnology
- China NHC – Original D-Allulose New Food Ingredient Authorization, Announcement No. 4 of 2025
HPA-Global works closely with strategic regulatory partner CIRS Group to support dietary supplement, functional food, and nutritional ingredient companies with regulatory consulting, ingredient approvals, GRAS notifications, and international market-entry strategies across China, the United States, Europe, Japan, South Korea, and other markets.
For more details, visit www.hpaglobal.org/connect.